Recent advances in developing therapeutics for cystic fibrosis

Human Molecular Genetics

Volumn 27, Issue 2, 2018, Pages R173-R186

  Strug, Lisa J ^a,b,c   Stephenson, Anne L ^d,e   Panjwani, Naim ^c   Harris, Ann ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHENOL DERIVATIVE; CFTR PROTEIN, HUMAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; QUINOLONE DERIVATIVE;

CYSTIC FIBROSIS; GENE THERAPY; GENETICS; GENOTYPE; HUMAN; MUTATION; PHENOTYPE; PHYSIOLOGY; PROCEDURES;

AMINOPHENOLS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC THERAPY; GENOTYPE; HUMANS; MUTATION; PHENOTYPE; QUINOLONES;

EID: 85057901150     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddy188     Document Type: Review

References (126)

1. Sosnay, P.R., Siklosi, K.R., Van Goor, F., Kaniecki, K., Yu, H., Sharma, N., Ramalho, A.S., Amaral, M.D., Dorfman, R., Zielenski, J. et al. (2013) Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat. Genet., 45, 1160 1167
2. Ramsey, B.W., Davies, J., McElvaney, N.G., Tullis, E., Bell, S.C., Drev?nek, P., Griese, M., McKone, E.F., Wainwright, C.E., Konstan, M.W. et al. (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med., 365, 1663 1672
3. Sawicki, G.S., McKone, E.F., Pasta, D.J., Millar, S.J., Wagener, J.S., Johnson, C.A. and Konstan, M.W. (2015) Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am. J. Respir. Crit. Care Med., 192, 836 842
4. Wainwright, C.E., Elborn, J.S., Ramsey, B.W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J.C., De Boeck, K., Flume, P.A. et al. (2015) Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N. Engl. J. Med., 373, 220 231
5. Taylor-Cousar, J.L., Munck, A., McKone, E.F., van der Ent, C.K., Moeller, A., Simard, C., Wang, L.T., Ingenito, E.P., McKee, C., Lu, Y. et al. (2017) Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N. Engl. J. Med., 377, 2013 2023
6. Rowe, S.M., Daines, C., Ringshausen, F.C., Kerem, E., Wilson, J., Tullis, E., Nair, N., Simard, C., Han, L., Ingenito, E.P. et al. (2017) Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis. N. Engl. J. Med., 377, 2024 2035
7. Martiniano, S.L., Toprak, D., Ong, T., Zemanick, E.T., Daines, C.L., Muhlebach, M.S., Esther, C.R., Jr and Dellon, E.P. (2018) Highlights from the 2017 North American Cystic Fibrosis Conference. Pediatr. Pulmonol, 53, 979 986
8. Howard, M., Frizzell, R.A. and Bedwell, D.M. (1996) Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med., 2, 467 469
9. Wilschanski, M., Yahav, Y., Yaacov, Y., Blau, H., Bentur, L., Rivlin, J., Aviram, M., Bdolah-Abram, T., Bebok, Z., Shushi, L. et al. (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med., 349, 1433 1441
10. Aslam, A., Jahnke, N., Remmington, T. and Southern, K.W. (2017) Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. Paediatr. Respir. Rev., 24, 32 34
11. Baradaran-Heravi, A., Niesser, J., Balgi, A.D., Choi, K., Zimmerman, C., South, A.P., Anderson, H.J., Strynadka, N.C., Bally, M.B. and Roberge, M. (2017) Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity. Proc. Natl. Acad. Sci. U S A, 114, 3479 3484
12. Linde, L. and Kerem, B. (2011) Nonsense-mediated mRNA decay and cystic fibrosis. Methods Mol. Biol., 741, 137 154
13. Aartsma-Rus, A., Straub, V., Hemmings, R., Haas, M., Schlosser-Weber, G., Stoyanova-Beninska, V., Mercuri, E., Muntoni, F., Sepodes, B., Vroom, E. et al. (2017) Development of exon skipping therapies for duchenne muscular dystrophy: A critical review and a perspective on the outstanding issues. Nucleic Acids Ther., 27, 251 259
14. Bowerman, M., Becker, C.G., Yanez-Munoz, R.J., Ning, K., Wood, M.J.A., Gillingwater, T.H., Talbot, K. and Consortium, U.S.R. (2017) Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis. Model. Mech., 10, 943 954
15. Friedman, K.J., Kole, J., Cohn, J.A., Knowles, M.R., Silverman, L.M. and Kole, R. (1999) Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J. Biol. Chem., 274, 36193 36199
16. Igreja, S., Clarke, L.A., Botelho, H.M., Marques, L. and Amaral, M.D. (2016) Correction of a cystic fibrosis splicing mutation by antisense oligonucleotides. Hum. Mutat., 37, 209 215
17. Lee, C.M., Flynn, R., Hollywood, J.A., Scallan, M.F. and Harrison, P.T. (2012) Correction of the DeltaF508 mutation in the cystic fibrosis transmembrane conductance regulator gene by zinc-finger nuclease homology-directed repair. Biores. Open Access, 1, 99 108
18. Crane, A.M., Kramer, P., Bui, J.H., Chung, W.J., Li, X.S., Gonzalez-Garay, M.L., Hawkins, F., Liao, W., Mora, D., Choi, S. et al. (2015) Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells. Stem Cell Rep., 4, 569 577
19. Schwank, G., Koo, B.K., Sasselli, V., Dekkers, J.F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C.K. et al. (2013) Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell, 13, 653 658
20. Sanz, D.J., Hollywood, J.A., Scallan, M.F. and Harrison, P.T. (2017) Cas9/gRNA targeted excision of cystic fibrosis-causing deep-intronic splicing mutations restores normal splicing of CFTR mRNA. PLoS One, 12, e0184009
21. Ott, C.J., Blackledge, N.P., Kerschner, J.L., Leir, S.H., Crawford, G.E., Cotton, C.U. and Harris, A. (2009) Intronic enhancers coordinate epithelial-specific looping of the active CFTR locus. Proc. Natl. Acad. Sci. U S A, 106, 19934 19939
22. Gheldof, N., Smith, E.M., Tabuchi, T.M., Koch, C.M., Dunham, I., Stamatoyannopoulos, J.A. and Dekker, J. (2010) Cell-Type-specific long-range looping interactions identify distant regulatory elements of the CFTR gene. Nucleic Acids Res., 38, 4325 4336
23. Yang, R., Kerschner, J.L., Gosalia, N., Neems, D., Gorsic, L.K., Safi, A., Crawford, G.E., Kosak, S.T., Leir, S.H. and Harris, A. (2016) Differential contribution of cis-regulatory elements to higher order chromatin structure and expression of the CFTR locus. Nucleic Acids Res., 44, 3082 3094
24. Smith, E.M., Lajoie, B.R., Jain, G. and Dekker, J. (2016) Invariant TAD boundaries constrain cell-Type-specific looping interactions between promoters and distal elements around the CFTR locus. Am. J. Hum. Genet., 98, 185 201
25. Schneider, C.S., Xu, Q., Boylan, N.J., Chisholm, J., Tang, B.C., Schuster, B.S., Henning, A., Ensign, L.M., Lee, E., Adstamongkonkul, P. et al. (2017) Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Sci. Adv., 3, e1601556
26. Loring, H.S., ElMallah, M.K. and Flotte, T.R. (2016) Development of rAAV2-CFTR: history of the first rAAV vector product to be used in humans. Hum. Gene Ther. Methods, 27, 49 58
27. Zhang, Z., Leir, S.H. and Harris, A. (2013) Immune mediators regulate CFTR expression through a bifunctional airway-selective enhancer. Mol. Cell. Biol., 33, 2843 2853
28. Zhang, Z., Leir, S.H. and Harris, A. (2014) Oxidative stress regulates CFTR gene expression in human airway epithelial cells through a distal antioxidant response element. Am. J. Respir. Cell. Mol. Biol., 33, 2843 2853
29. Mutolo, M.J., Leir, S.H., Fossum, S.L., Browne, J.A. and Harris, A. (2018) A transcription factor network represses CFTR gene expression in airway epithelial cells. Biochem. J., 475, 1323 1334
30. Bischof, J.M., Ott, C.J., Leir, S.H., Gosalia, N., Song, L., London, D., Furey, T.S., Cotton, C.U., Crawford, G.E. and Harris, A. (2012) A genome-wide analysis of open chromatin in human tracheal epithelial cells reveals novel candidate regulatory elements for lung function. Thorax, 67, 385 391
31. Gillen, A.E., Yang, R., Cotton, C.U., Perez, A., Randell, S.H., Leir, S.H. and Harris, A. (2018) Molecular characterization of gene regulatory networks in primary human tracheal and bronchial epithelial cells. J. Cyst. Fibros., 17, 444 453
32. Saint-Criq, V. and Gray, M.A. (2017) Role of CFTR in epithelial physiology. Cell. Mol. Life Sci., 74, 93 115
33. Haq, I.J., Gray, M.A., Garnett, J.P., Ward, C. and Brodlie, M. (2016) Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets. Thorax, 71, 284 287
34. Knowles, M.R. and Boucher, R.C. (2002) Mucus clearance as a primary innate defense mechanism for mammalian airways. J. Clin. Invest., 109, 571 577
35. Martin, S.L., Saint-Criq, V., Hwang, T.C. and Csanady, L. (2018) Ion channels as targets to treat cystic fibrosis lung disease. J. Cyst. Fibros, 17, S22 S27
36. Mall, M.A. and Galietta, L.J. (2015) Targeting ion channels in cystic fibrosis. J. Cyst. Fibros., 14, 561 570
37. Inglis, S.K., Corboz, M.R. and Ballard, S.T. (1998) Effect of anion secretion inhibitors on mucin content of airway submucosal gland ducts. Am. J. Physiol., 274, L762 L766
38. Blackman, S.M., Commander, C.W., Watson, C., Arcara, K.M., Strug, L.J., Stonebraker, J.R., Wright, F.A., Rommens, J.M., Sun, L., Pace, R.G. et al. (2013) Genetic modifiers of cystic fibrosis-related diabetes. Diabetes, 62, 3627 3635
39. Strug, L.J. (2016) Meta-GWAS identifies modifiers of meconium ileus susceptibility in cystic fibrosis. In The 30th Annual North American Cystic Fibrosis Conference, Orlando, FL. 40. Sun, L., Rommens, J.M., Corvol, H., Li, W., Li, X., Chiang, T.A., Lin, F., Dorfman, R., Busson, P.F., Parekh, R.V. et al. (2012) Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat. Genet., 44, 562 569
40. Strug, L.J., Gonska, T., He, G., Keenan, K., Ip, W., Boelle, P.Y., Lin, F., Panjwani, N., Gong, J., Li, W. et al. (2016) Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. Hum. Mol. Genet., 25, 4590 4600
41. Di Paola, M., Park, A.J., Ahmadi, S., Roach, E.J., Wu, Y.S., Struder-Kypke, M., Lam, J.S., Bear, C.E. and Khursigara, C.M. (2017) SLC6A14 is a genetic modifier of cystic fibrosis that regulates Pseudomonas aeruginosa attachment to human bronchial epithelial cells. MBio, 8, e02073 17
42. Reihill, J.A., Walker, B., Hamilton, R.A., Ferguson, T.E., Elborn, J.S., Stutts, M.J., Harvey, B.J., Saint-Criq, V., Hendrick, S.M. and Martin, S.L. (2016) Inhibition of protease-epithelial sodium channel signaling improves mucociliary function in cystic fibrosis airways. Am. J. Respir. Crit. Care Med., 194, 701 710
43. Douglas, L., Ferguson, T., Reihill, J. and Martin, L. (2017) An Investigation into novel inhibitors of channel activating proteases with implicators for cystic fibrosis lung disease. In 14th European Cystic Fibrosis Society Basic Science Conference, Albufeira, Portugal. 45. Scott, D.W., Walker, M.P., Sesma, J., Wu, B., Stuhlmiller, T.J., Sabater, J.R., Abraham, W.M., Crowder, T.M., Christensen, D.J. and Tarran, R. (2017) SPX-101 is a novel epithelial sodium channel-Targeted therapeutic for cystic fibrosis that restores mucus transport.Am. J. Respir. Crit. CareMed., 196, 734 744
44. Clark, K.L., Hughes, S.A., Bulsara, P., Coates, J., Moores, K., Parry, J., Carr, M., Mayer, R.J., Wilson, P., Gruenloh, C. et al. (2013) Pharmacological characterization of a novel ENaCalpha siRNA (GSK2225745) with potential for the treatment of cystic fibrosis. Mol. Ther. Nucleic Acids, 2, e65
45. Crosby, J.R., Zhao, C., Jiang, C., Bai, D., Katz, M., Greenlee, S., Kawabe, H., McCaleb, M., Rotin, D., Guo, S. et al. (2017) Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice. J. Cyst. Fibros, 16, 671 680
46. Coote, K.J., Paisley, D., Czarnecki, S., Tweed, M., Watson, H., Young, A., Sugar, R., Vyas, M., Smith, N.J., Baettig, U. et al. (2015) NVP-QBE170: An inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia. Br. J. Pharmacol., 172, 2814 2826
47. Gardiner, P., Malmgren, A., Ersdal, E., Goldwater, R. and Patel, N. (2017) Enac inhibitor Azd5634 first in human trial reveals promising clinical profile for the treatment of cystic fibrosis. Am. J. Resp. Crit. Care, 195, A7306
48. Libby, E.F., Fortinberry, H., Birket, S., Astrand, A., Patel, N., Malmgren, A., Tearney, G.J. and Rowe, S. (2017) Enac inhibitor Azd5634 augments airway surface liquid and mucociliary transport in primary cystic fibrosis airway cells. Am J Resp Crit Care, 195, 6466
49. Libby, E.F., Fortinberry, H.K., Adewale, T., Fu, I., Astrand, A., Patel, N., Malmgren, A., Tearney, G. and Rowe, S.M. (2017) Enac inhibitor Azd5634 increases mucociliary transport alone and in combination with lumacaftor/ivacaftor in primary Cf Hbe cells. Pediatr. Pulm., 52, S320 S320
50. Enterprise Therapeutics. (2018) Identifying pathways regulating goblet cell metaplasia: phenotypic screening with bronchospheres. In European Cystic Fibrosis Society Basic Science Meeting, Loutraki, Greece. 53. Enterprise Therapeutics. (2016) Pharmacological characterisation of TMEM16A regulators. In The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy. 54. Canessa, C.M., Schild, L., Buell, G., Thorens, B., Gautschi, I., Horisberger, J.D. and Rossier, B.C. (1994) Amiloride-sensitive epithelial Na channel is made of three homologous subunits. Nature, 367, 463 467
51. Gaillard, E.A., Kota, P., Gentzsch, M., Dokholyan, N.V., Stutts, M.J. and Tarran, R. (2010) Regulation of the epithelial Na channel and airway surface liquid volume by serine proteases. Pflugers Arch., 460, 1 17
52. Myerburg, M.M., Harvey, P.R., Heidrich, E.M., Pilewski, J.M. and Butterworth, M.B. (2010) Acute regulation of the epithelial sodium channel in airway epithelia by proteases and trafficking. Am. J. Respir. Cell. Mol. Biol., 43, 712 719
53. Garcia-Caballero, A., Rasmussen, J.E., Gaillard, E., Watson, M.J., Olsen, J.C., Donaldson, S.H., Stutts, M.J. and Tarran, R. (2009) SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage. Proc. Natl. Acad. Sci. U S A, 106, 11412 11417
54. Graham, A., Hasani, A., Alton, E.W., Martin, G.P., Marriott, C., Hodson, M.E., Clarke, S.W. and Geddes, D.M. (1993) No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur. Respir. J., 6, 1243 1248
55. Knowles, M.R., Church, N.L., Waltner, W.E., Yankaskas, J.R., Gilligan, P., King, M., Edwards, L.J., Helms, R.W. and Boucher, R.C. (1990) A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N. Engl. J. Med., 322, 1189 1194
56. Hofmann, T., Stutts, M.J., Ziersch, A., Ruckes, C., Weber, W.M., Knowles, M.R., Lindemann, H. and Boucher, R.C. (1998) Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis. Am. J. Respir. Crit. Care Med., 157, 1844 1849
57. Pons, G., Marchand, M.C., d Athis, P., Sauvage, E., Foucard, C., Chaumet-Riffaud, P., Sautegeau, A., Navarro, J. and Lenoir, G. (2000) French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group. Pediatr. Pulmonol., 30, 25 31
58. Hirsh, A.J., Sabater, J.R., Zamurs, A., Smith, R.T., Paradiso, A.M., Hopkins, S., Abraham, W.M. and Boucher, R.C. (2004) Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J. Pharmacol. Exp. Ther., 311, 929 938
59. Zhou, Z., Treis, D., Schubert, S.C., Harm, M., Schatterny, J., Hirtz, S., Duerr, J., Boucher, R.C. and Mall, M.A. (2008) Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. Am. J. Respir. Crit. Care Med., 178, 1245 1256
60. O Riordan, T.G., Donn, K.H., Hodsman, P., Ansede, J.H., Newcomb, T., Lewis, S.A., Flitter, W.D., White, V.S., Johnson, M.R., Montgomery, A.B. et al. (2014) Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: phase 1 trial of GS-9411. J. Aerosol. Med. Pulm. Drug Deliv., 27, 200 208
61. Bridges, R.J., Newton, B.B., Pilewski, J.M., Devor, D.C., Poll, C.T. and Hall, R.L. (2001) Na transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. Am. J. Physiol. Lung Cell. Mol. Physiol., 281, L16 L23
62. Coote, K., Atherton-Watson, H.C., Sugar, R., Young, A., MacKenzie-Beevor, A., Gosling, M., Bhalay, G., Bloomfield, G., Dunstan, A., Bridges, R.J. et al. (2009) Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-Activating protease. J. Pharmacol. Exp. Ther., 329, 764 774
63. Martin, L., Reihill, J., Douglas, L., Ferguson, T. and Walker, B. (2017) Detection and inhibition of ENaC-Activating proteases associated with airway dehydration in COPD. Eur. Respir. J., 50, PA4933
64. Manunta, M.D.I., Tagalakis, A.D., Attwood, M., Aldossary, A.M., Barnes, J.L., Munye, M.M., Weng, A., McAnulty, R.J. and Hart, S.L. (2017) Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: A therapeutic strategy for cystic fibrosis. Sci. Rep., 7, 700
65. Caputo, A., Caci, E., Ferrera, L., Pedemonte, N., Barsanti, C., Sondo, E., Pfeffer, U., Ravazzolo, R., Zegarra-Moran, O. and Galietta, L.J. (2008) TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science, 322, 590 594
66. Schroeder, B.C., Cheng, T., Jan, Y.N. and Jan, L.Y. (2008) Expression cloning of TMEM16A as a calcium-Activated chloride channel subunit. Cell, 134, 1019 1029
67. Yang, Y.D., Cho, H., Koo, J.Y., Tak, M.H., Cho, Y., Shim, W.S., Park, S.P., Lee, J., Lee, B., Kim, B.M. et al. (2008) TMEM16A confers receptor-Activated calcium-dependent chloride conductance. Nature, 455, 1210 1215
68. Jung, J., Nam, J.H., Park, H.W., Oh, U., Yoon, J.H. and Lee, M.G. (2013) Dynamic modulation of ANO1/TMEM16A HCO3(-) permeability by Ca2 /calmodulin. Proc. Natl. Acad. Sci. U S A, 110, 360 365
69. Sondo, E., Caci, E. and Galietta, L.J. (2014) The TMEM16A chloride channel as an alternative therapeutic target in cystic fibrosis. Int. J. Biochem. Cell Biol., 52, 73 76
70. Li, H., Salomon, J.J., Sheppard, D.N., Mall, M.A. and Galietta, L.J. (2017) Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport. Curr. Opin. Pharmacol., 34, 91 97
71. Accurso, F.J., Moss, R.B., Wilmott, R.W., Anbar, R.D., Schaberg, A.E., Durham, T.A., Ramsey, B.W. and Group, T.-I.S. (2011) Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am. J. Respir. Crit. Care Med., 183, 627 634
72. Ratjen, F., Durham, T., Navratil, T., Schaberg, A., Accurso, F.J., Wainwright, C., Barnes, M., Moss, R.B.; TIGER-2 Study Investigator Group (2012) Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J. Cyst. Fibros, 11, 539 549
73. Mason, S.J., Paradiso, A.M. and Boucher, R.C. (1991) Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium. Br. J. Pharmacol., 103, 1649 1656
74. Namkung, W., Yao, Z., Finkbeiner, W.E. and Verkman, A.S. (2011) Small-molecule activators of TMEM16A, a calcium-Activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction. FASEB J., 25, 4048 4062
75. Benedetto, R., Ousingsawat, J., Wanitchakool, P., Zhang, Y., Holtzman, M.J., Amaral, M., Rock, J.R., Schreiber, R. and Kunzelmann, K. (2017) Epithelial chloride transport by CFTR requires TMEM16A. Sci. Rep., 7, 12397
76. Lerias, J., Pinto, M., Benedetto, R., Schreiber, R., Amaral, M., Aureli, M. and Kunzelmann, K. (2018) Compartmentalized crosstalk of CFTR and TMEM16A (ANO1) through EPAC1 and ADCY1. Cell Signal., 44, 10 19
77. Valkenier, H. and Davis, A.P. (2013) Making a match for Valinomycin: steroidal scaffolds in the design of electroneutral, electrogenic anion carriers. Acc. Chem. Res., 46, 2898 2909
78. Hussain, S., Brotherhood, P.R., Judd, L.W. and Davis, A.P. (2011) Diaxial diureido decalins as compact, efficient, and tunable anion transporters. J. Am. Chem. Soc., 133, 1614 1617
79. Li, H., Valkenier, H., Judd, L.W., Brotherhood, P.R., Hussain, S., Cooper, J.A., Jurcek, O., Sparkes, H.A., Sheppard, D.N. and Davis, A.P. (2016) Efficient, non-Toxic anion transport by synthetic carriers in cells and epithelia. Nat. Chem., 8, 24 32
80. Nelson, M.R., Tipney, H., Painter, J.L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P.C., Li, M.J., Wang, J. et al. (2015) The support of human genetic evidence for approved drug indications. Nat. Genet., 47, 856 860
81. Emond, M.J., Louie, T., Emerson, J., Zhao, W., Mathias, R.A., Knowles, M.R., Wright, F.A., Rieder, M.J., Tabor, H.K., Nickerson, D.A. et al. (2012) Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat. Genet., 44, 886 889
82. Emond, M.J., Louie, T., Emerson, J., Chong, J.X., Mathias, R.A., Knowles, M.R., Rieder, M.J., Tabor, H.K., Nickerson, D.A., Barnes, K.C. et al. (2015) Exome sequencing of phenotypic extremes identifies CAV2 and TMC6 as interacting modifiers of chronic Pseudomonas aeruginosa infection in cystic fibrosis. PLoS Genet., 11, e1005273
83. Wright, F.A., Strug, L.J., Doshi, V.K., Commander, C.W., Blackman, S.M., Sun, L., Berthiaume, Y., Cutler, D., Cojocaru, A., Collaco, J.M. et al. (2011) Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat. Genet., 43, 539 546
84. Soave, D., Corvol, H., Panjwani, N., Gong, J., Li, W., Boelle, P.Y., Durie, P.R., Paterson, A.D., Rommens, J.M., Strug, L.J. et al. (2015) A joint location-scale test improves power to detect associated SNPs, gene sets, and pathways. Am. J. Hum. Genet., 97, 125 138
85. Corvol, H., Blackman, S.M., Boelle, P.Y., Gallins, P.J., Pace, R.G., Stonebraker, J.R., Accurso, F.J., Clement, A., Collaco, J.M., Dang, H. et al. (2015) Genome-wide association meta-Analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nat. Commun., 6, 8382
86. Bertrand, C.A., Zhang, R., Pilewski, J.M. and Frizzell, R.A. (2009) SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. J. Gen. Physiol., 133, 421 438
87. Bertrand, C.A., Mitra, S., Mishra, S.K., Wang, X., Zhao, Y., Pilewski, J.M., Madden, D.R. and Frizzell, R.A. (2017) The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9. Am. J. Physiol. Lung Cell. Mol. Physiol., 312, L912 L925
88. Salomon, J.J., Spahn, S., Wang, X., Fullekrug, J., Bertrand, C.A. and Mall, M.A. (2016) Generation and functional characterization of epithelial cells with stable expression of SLC26A9 Cl-channels. Am. J. Physiol. Lung Cell. Mol. Physiol., 310, L593 L602
89. Liu, X., Li, T., Riederer, B., Lenzen, H., Ludolph, L., Yeruva, S., Tuo, B., Soleimani, M. and Seidler, U. (2015) Loss of Slc26a9 anion transporter alters intestinal electrolyte and HCO3(-) transport and reduces survival in CFTR-deficient mice. Pflugers Arch., 467, 1261 1275
90. Miller, M.R., Soave, D., Li, W., Gong, J., Pace, R.G., Boelle, P.Y., Cutting, G.R., Drumm, M.L., Knowles, M.R., Sun, L. et al. (2015) Variants in solute carrier SLC26A9 modify prenatal exocrine pancreatic damage in cystic fibrosis. J. Pediatr., 166, 1152 1157 e1156
91. Soave, D., Miller, M.R., Keenan, K., Li, W., Gong, J., Ip, W., Accurso, F., Sun, L., Rommens, J.M., Sontag, M. et al. (2014) Evidence for a causal relationship between early exocrine pancreatic disease and cystic fibrosis-related diabetes: A Mendelian randomization study. Diabetes, 63, 2114 2119
92. Hart, N.J., Aramandla, R., Poffenberger, G., Fayolle, C., Thames, A.H., Bautista, A., Spigelman, A.F., Babon, J.A.B., DeNicola, M.E., Dadi, P.K. et al. (2018) Cystic fibrosis-related diabetes is caused by islet loss and inflammation. JCI Insight, 3, e98240
93. Sato, Y., Robert, R., Thomas, D.Y. and Hanrahan, J.W. (2017) SLC26A9 is prematurely degraded along with misfolded F508del-CFTR. In the 14th European Cystic Fibrosis Society, Albufeira, Portugal. 98. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O Connell, J. et al. (2017) Genome-wide genetic data on 500, 000 UK Biobank participants. bioRxiv. doi:10.1101/166298
94. Anagnostopoulou, P., Riederer, B., Duerr, J., Michel, S., Binia, A., Agrawal, R., Liu, X., Kalitzki, K., Xiao, F., Chen, M. et al. (2012) SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation. J. Clin. Invest., 122, 3629 3634
95. GTEx Consortium. (2013) The Genotype-Tissue Expression (GTEx) project. Nat. Genet., 45, 580 585
96. Zegarra-Moran, O., Folli, C., Manzari, B., Ravazzolo, R., Varesio, L. and Galietta, L.J. (2004) Double mechanism for apical tryptophan depletion in polarized human bronchial epithelium. J. Immunol., 173, 542 549
97. Gorrieri, G., Scudieri, P., Caci, E., Schiavon, M., Tomati, V., Sirci, F., Napolitano, F., Carrella, D., Gianotti, A., Musante, I. et al. (2016) Goblet cell hyperplasia requires high bicarbonate transport to support mucin release. Sci. Rep., 6, 36016
98. Galietta, L.J., Folli, C., Marchetti, C., Romano, L., Carpani, D., Conese, M. and Zegarra-Moran, O. (2000) Modification of transepithelial ion transport in human cultured bronchial epithelial cells by interferon-gamma. Am. J. Physiol. Lung Cell. Mol. Physiol., 278, L1186 L1194
99. Bradford, E.M., Sartor, M.A., Gawenis, L.R., Clarke, L.L. and Shull, G.E. (2009) Reduced NHE3-mediated Na absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice. Am. J. Physiol. Gastrointest. Liver Physiol., 296, G886 G898
100. Shah, V.S., Meyerholz, D.K., Tang, X.X., Reznikov, L., Abou Alaiwa, M., Ernst, S.E., Karp, P.H., Wohlford-Lenane, C.L., Heilmann, K.P., Leidinger, M.R. et al. (2016) Airway acidification initiates host defense abnormalities in cystic fibrosis mice. Science, 351, 503 507
101. Ma, J., Rubin, B.K. and Voynow, J.A. (2017) Mucins, mucus, and goblet cells. Chest, doi:10.1016/j.chest.2017.11.008
102. Schultheis, P.J., Clarke, L.L., Meneton, P., Miller, M.L., Soleimani, M., Gawenis, L.R., Riddle, T.M., Duffy, J.J., Doetschman, T., Wang, T. et al. (1998) Renal and intestinal absorptive defects in mice lacking the NHE3 Na /H exchanger. Nat. Genet., 19, 282 285
103. Donowitz, M. and Li, X. (2007) Regulatory binding partners and complexes of NHE3. Physiol. Rev., 87, 825 872
104. O Neal, W.K., Gallins, Paul., Pace, R.G., Dang, H., Wolf, W.E., Jones, L.C., Guo, X.L., Zhou, Y.-H., Madar, V., Huang, J. et al. (2015) Gene expression in transformed lymphocytes reveals variation in endomembrane and HLA pathways modifying cystic fibrosis pulmonary phenotypes. Am. J. Hum. Genet., 96, 318 328
105. Polineni, D., Dang, H., Gallins, P.J., Jones, L.C., Pace, R.G., Stonebraker, J.R., Commander, L.A., Krenicky, J.E., Zhou, Y.H., Corvol, H. et al. (2018) Airway mucosal host defense is key to genomic regulation of cystic fibrosis lung disease severity. Am. J. Respir. Crit. Care Med., 197, 79 93
106. Stolzenburg, L.R., Yang, R., Kerschner, J.L., Fossum, S., Xu, M., Hoffmann, A., Lamar, K.M., Ghosh, S., Wachtel, S., Leir, S.H. et al. (2017) Regulatory dynamics of 11p13 suggest a role for EHF in modifying CF lung disease severity. Nucleic Acids Res., 45, 8773 8784
107. Stanke, F., van Barneveld, A., Hedtfeld, S., Wolfl, S., Becker, T. and Tummler, B. (2014) The CF-modifying gene EHF promotes p.Phe508del-CFTR residual function by altering protein glycosylation and trafficking in epithelial cells. Eur. J. Hum. Genet., 22, 660 666
108. Fossum, S.L., Mutolo, M.J., Yang, R., Dang, H., O Neal, W.K., Knowles, M.R., Leir, S.H. and Harris, A. (2014) Ets homologous factor regulates pathways controlling response to injury in airway epithelial cells. Nucleic Acids Res., 42, 13588 13598
109. Fossum, S.L., Mutolo, M.J., Tugores, A., Ghosh, S., Randell, S.H., Jones, L.C., Leir, S.H. and Harris, A. (2017) Ets homologous factor (EHF) has critical roles in epithelial dysfunction in airway disease. J. Biol. Chem., 292, 10938 10949
110. Joshi, N., Darrah, R., Mitchell, A., Eastman, J., Gopinath, N., Jacono, F. and Drumm, M. (2013) Alleles of the AGTR2 gene affect gene expression and airway mechanics in CF. Pediatr. Pulmonol., 48, 265
111. Darrah, R.J., Jacono, F.J., Joshi, N., Mitchell, A.L., Sattar, A., Campanaro, C.K., Litman, P., Frey, J., Nethery, D.E., Barbato, E.S. et al. (2018) AGTR2 absence or antagonism prevents cystic fibrosis pulmonary manifestations. J. Cyst. Fibros., doi: 10.1016/j.jcf.2018.05.013
112. Galietta, L.J., Musante, L., Romio, L., Caruso, U., Fantasia, A., Gazzolo, A., Romano, L., Sacco, O., Rossi, G.A., Varesio, L. et al. (1998) An electrogenic amino acid transporter in the apical membrane of cultured human bronchial epithelial cells. Am. J. Physiol., 275, L917 L923
113. Loriol, C., Dulong, S., Avella, M., Gabillat, N., Boulukos, K., Borgese, F. and Ehrenfeld, J. (2008) Characterization of SLC26A9, facilitation of Cl(-) transport by bicarbonate. Cell. Physiol. Biochem., 22, 15 30
114. Ohana, E., Yang, D., Shcheynikov, N. and Muallem, S. (2009) Diverse transport modes by the solute carrier 26 family of anion transporters. J. Physiol., 587, 2179 2185
115. Chang, M.H., Plata, C., Sindic, A., Ranatunga, W.K., Chen, A.P., Zandi-Nejad, K., Chan, K.W., Thompson, J., Mount, D.B. and Romero, M.F. (2009) Slc26a9 is inhibited by the R-region of the cystic fibrosis transmembrane conductance regulator via the STAS domain. J. Biol. Chem., 284, 28306 28318
116. Avella, M., Loriol, C., Boulukos, K., Borgese, F. and Ehrenfeld, J. (2011) SLC26A9 stimulates CFTR expression and function in human bronchial cell lines. J. Cell. Physiol., 226, 212 223
117. Ousingsawat, J., Schreiber, R. and Kunzelmann, K. (2012) Differential contribution of SLC26A9 to Cl(-) conductance in polarized and non-polarized epithelial cells. J. Cell. Physiol., 227, 2323 2329
118. Karki, S., Tokito, M.K. and Holzbaur, E.L. (2000) A dynactin subunit with a highly conserved cysteine-rich motif interacts directly with Arp1. J. Biol. Chem., 275, 4834 4839
119. Schroder, J.M., Schneider, L., Christensen, S.T. and Pedersen, L.B. (2007) EB1 is required for primary cilia assembly in fibroblasts. Curr. Biol., 17, 1134 1139
120. King, S.M. (2012) Integrated control of axonemal dynein AAA( ) motors. J. Struct. Biol., 179, 222 228
121. Emond, M.J., Louie, T., Emerson, J., Chong, J.X., Mathias, R.A., Knowles, M.R., Rieder, M.J., Tabor, H.K., Nickerson, D.A., Barnes, K.C. et al. (2015) Correction: exome sequencing of phenotypic extremes identifies CAV2 and TMC6 as interacting modifiers of chronic pseudomonas aeruginosa infection in cystic fibrosis. PLoS Genet., 11, e1005424
122. Zaas, D.W., Swan, Z.D., Brown, B.J., Li, G., Randell, S.H., Degan, S., Sunday, M.E., Wright, J.R. and Abraham, S.N. (2009) Counteracting signaling activities in lipid rafts associated with the invasion of lung epithelial cells by Pseudomonas aeruginosa. J. Biol. Chem., 284, 9955 9964
123. Lazarczyk, M., Dalard, C., Hayder, M., Dupre, L., Pignolet, B., Majewski, S., Vuillier, F., Favre, M. and Liblau, R.S. (2012) EVER proteins, key elements of the natural anti-human papillomavirus barrier, are regulated upon T-cell activation. PLoS One, 7, e39995
124. Lennox, A.T., Coburn, S.L., Leech, J.A., Heidrich, E.M., Kleyman, T.R.,Wenzel, S.E., Pilewski, J.M., Corcoran, T.E. and Myerburg,M.M. (2018) ATP12A promotesmucus dysfunction during Type 2 airway inflammation. Sci. Rep., 8, 2109
125. Novak, I., Wang, J., Henriksen, K.L., Haanes, K.A., Krabbe, S., Nitschke, R. and Hede, S.E. (2011) Pancreatic bicarbonate secretion involves two proton pumps. J. Biol. Chem., 286, 280 289
126. McInnes, G., Tanigawa, Y., DeBoever, C., Lavertu, A., Olivieri, J.E., Aguirre, M. and Rivas, M. (2018) Global Biobank Engine: enabling genotype-phenotype browsing for biobank summary statistics. bioRxiv, doi: https://doi.org/10.1101/304188.